Results 191 to 200 of about 25,120 (238)
Pharmacotherapy Risks in Rare Genetic Diseases: Cross-Referencing ACMG Secondary Findings v3.2 List With Clinical Databases. [PDF]
Allen JD, Duong BQ, Brady J, Arn P.
europepmc +1 more source
Long-acting β<sub>2</sub> agonist (LABA) with a long-acting muscarinic receptor antagonist (LAMA) promotes human airway smooth muscle (HASM) relaxation and circumvents β<sub>2</sub> adrenergic receptor tachyphylaxis. [PDF]
Jude J +5 more
europepmc +1 more source
Emerging opportunities in ROP therapy: from inhibiting pathological vessel growth to promoting physiological vascularization. [PDF]
Filippi L +4 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
The FASEB Journal, 2022
Asthma is characterized by chronic airway inflammation and airway smooth muscle (ASM) cell contraction. Current treatments for asthma include beta‐agonists which activate the beta 2‐adrenergic receptor, a G protein‐coupled receptor (GPCR) that promotes Gs‐dependent production of cAMP leading to ASM relaxation.
Francesco De Pascali +9 more
openaire +1 more source
Asthma is characterized by chronic airway inflammation and airway smooth muscle (ASM) cell contraction. Current treatments for asthma include beta‐agonists which activate the beta 2‐adrenergic receptor, a G protein‐coupled receptor (GPCR) that promotes Gs‐dependent production of cAMP leading to ASM relaxation.
Francesco De Pascali +9 more
openaire +1 more source
Adrenergic Beta Agonists and Anticholinergics in Obstructive Lung Diseases
Journal of Aerosol Medicine, 1997ABSTRACT Airflow obstruction in chronic obstructive pulmonary disease (COPD) is due to the combination of airway disease and emphysema, may be accompanied by airway reactivity, and may be partially reversible. Aerosol deposition is affected by airway geometry.
ETIENNE LEMARIÉ, PATRICE DIOT
openaire +1 more source

